Fahr Syndrome: Clinical Features, Diagnosis, and Management
Fahr syndrome is a rare neurological disorder characterized by bilateral intracranial calcifications (primarily in the basal ganglia) associated with metabolic abnormalities—most commonly hypoparathyroidism—requiring immediate correction of hypocalcemia and long-term metabolic control to prevent neurological complications and improve outcomes.
Clinical Features
Neurological Manifestations
Fahr syndrome presents with a broad spectrum of neurological symptoms 1, 2, 3:
- Seizures: Generalized tonic-clonic seizures are the most common acute presentation, often triggered by severe hypocalcemia
- Movement disorders: Parkinsonism, chorea, tremors, and gait instability
- Cognitive decline: Progressive deterioration in memory, concentration, and executive function
- Altered consciousness: Ranging from confusion to decreased consciousness requiring emergency intervention
Neuropsychiatric Symptoms
The psychiatric manifestations can be prominent and may precede other symptoms 4:
- Behavioral disturbances and disinhibition
- Hallucinations and psychotic symptoms
- Mood disorders (bipolar-like presentations)
- Personality changes
Associated Physical Findings
Look specifically for 1, 2, 3:
- Cataracts (bilateral)
- History of thyroidectomy or neck surgery
- Signs of chronic hypocalcemia (Chvostek's sign, Trousseau's sign)
- Dental abnormalities
Diagnostic Workup
Laboratory Evaluation (Priority)
- Serum calcium (expect severe hypocalcemia, often <5 mg/dL)
- Parathyroid hormone (PTH) (typically low or inappropriately normal)
- Phosphate (elevated or borderline elevated)
- Magnesium (can affect PTH secretion)
- Vitamin D levels (25-OH and 1,25-dihydroxy)
- Alkaline phosphatase
- Renal function (creatinine, BUN)
Neuroimaging
Non-contrast head CT is the diagnostic imaging modality of choice 2, 3, 5:
- Reveals bilateral, symmetrical calcifications in:
- Basal ganglia (most common)
- Thalamus
- Cerebellum (dentate nucleus)
- Subcortical white matter
- Cerebral cortex
MRI provides additional detail but CT is superior for detecting calcifications 5.
Additional Investigations
- EEG: To evaluate for seizure activity and diffuse encephalopathy 3
- Exclude secondary causes: Rule out infectious (TORCH, HIV, toxoplasmosis), autoimmune, and toxic etiologies 1, 2
- Genetic testing: Consider when feasible to distinguish primary familial brain calcification (Fahr disease) from secondary Fahr syndrome, though financial constraints may limit access 6
Critical Diagnostic Distinction
Fahr Syndrome vs. Fahr Disease 3, 5:
- Fahr Syndrome (secondary): Calcifications due to identifiable metabolic cause (hypoparathyroidism, pseudohypoparathyroidism, hyperparathyroidism)
- Fahr Disease (primary familial brain calcification): Idiopathic, autosomal dominant inheritance, no metabolic abnormalities
This distinction is crucial because Fahr syndrome is treatable by addressing the underlying metabolic disorder, while Fahr disease lacks specific treatment 3.
Management
Acute Phase
For patients presenting with seizures and severe hypocalcemia 1, 2, 3:
Immediate calcium replacement:
- IV calcium gluconate for symptomatic hypocalcemia
- Monitor cardiac rhythm (risk of QT prolongation)
Seizure management:
- Antiepileptic drugs (levetiracetam, valproate, or phenytoin)
- Note: Seizures often resolve with calcium correction
Stabilization:
- Correct magnesium deficiency if present
- Monitor for cardiac complications
Long-Term Management
Maintenance therapy focuses on metabolic control 1, 3:
- Oral calcium supplementation (calcium carbonate or citrate)
- Vitamin D (calcitriol or ergocalciferol)
- Target serum calcium: Low-normal range (8.0-8.5 mg/dL) to avoid hypercalciuria
- Regular monitoring: Calcium, phosphate, renal function every 3-6 months
Symptomatic Treatment
For persistent neuropsychiatric symptoms 4:
- Mood stabilizers (lithium carbonate, oxcarbazepine) for bipolar-like presentations
- Low-dose antipsychotics (quetiapine, aripiprazole) for psychotic symptoms
- Cognitive rehabilitation when appropriate
Prognosis and Follow-Up
Early diagnosis and treatment can reverse the calcification process and restore mental function 5, though this is not universal. The key prognostic factors include:
- Duration of hypocalcemia: Chronic, untreated cases have worse outcomes
- Extent of calcifications: More extensive calcifications correlate with greater neurological impairment
- Timeliness of intervention: Early metabolic correction improves outcomes 1
Monitoring Strategy
- Neurology follow-up: For seizure management and neurological assessment
- Endocrinology follow-up: For metabolic control 2
- Repeat imaging: Not routinely necessary unless clinical deterioration occurs
- Neuropsychological evaluation: If cognitive symptoms persist
Important Caveats
Common pitfalls to avoid:
Misattributing symptoms to primary psychiatric disorder: The neuropsychiatric symptoms can precede recognition of metabolic abnormalities by years 4
Assuming physiological calcifications: Up to 20% of asymptomatic patients may have incidental basal ganglia calcifications on imaging, but the presence of neurological symptoms mandates full workup 4, 5
Overlooking hypoparathyroidism: Always inquire about prior neck surgery, even if remote (7+ years prior) 3
Incomplete metabolic workup: The absence of obvious endocrine history does not exclude hypoparathyroidism as the cause 2
Rare associations: Be aware that Fahr syndrome has been associated with intracranial aneurysms in extremely rare cases; consider vascular imaging if unexplained neurological deterioration occurs 7
In resource-limited settings where genetic testing is unavailable, focus on excluding treatable metabolic causes through comprehensive biochemical evaluation 6. The presence of metabolic abnormalities strongly suggests Fahr syndrome rather than primary Fahr disease, making treatment possible and potentially reversible.